



NC State Nephrology-Urology is enrolling patients with chronic kidney disease (CKD) to explore a new novel biomarker to aid in earlier detection of a common complication (acidosis) associated with kidney disease which will hopefully allow us to predict disease outcomes and therapeutic responses.

PARTICIPATION:

- Each cat will be seen for 4 study visits after enrollment into the study. These visits will occur every 3 months for one year
- At study enrollment each cat will have the following testing performed: a renal biochemistry panel, PCV/TP, urinalysis, urine protein-to-creatinine ratio, and blood pressure measurement
- At each study visit after enrollment each cat will have a renal biochemistry panel, urinalysis, and blood pressure measurement performed.

ELIGIBILITY:

- Cats diagnosed with stable IRIS stage II-IV CKD (serum creatinine > 1.6 mg/dL or SDMA > 18 and lack of appropriate urine concentration, USG < 1.045)
- Cats must be on a stable diet for 28 days prior to study enrollment
- Criteria that exclude participation:
 - Evidence of lower urinary tract infection based on urinalysis or urine culture
 - Cats receiving alkaline therapy (sodium bicarbonate or potassium citrate), diuretics or steroids.
 - Cats diagnosed with diagnosed with liver disease, or endocrinopathies such as unstable hyperthyroidism or diabetes mellitus.
 - Cats with a subcutaneous ureteral bypass system (SUB)

For additional information contact the Harris Lab:

harrislab-clinicaltrials@ncsu.edu

